Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid in Postmenopausal Osteoporosis
NCT01732770Phase 4Completed
- Sponsor
- Amgen
- Start
- Nov 2012
- Primary completion
- Jan 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of denosumab in postmenopausal osteoporosis (2 arms), sponsored by Amgen. Primary endpoint: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at 12 months. Started Nov 2012; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01732770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732770.